A First-in-Human Single Ascending Dose, Mass Balance, and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 in Healthy Adult Subjects
Latest Information Update: 25 Feb 2025
Price :
$35 *
At a glance
- Drugs ABBV 1088 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 19 Feb 2025 Status changed from active, no longer recruiting to completed.
- 24 Jan 2025 Planned End Date changed from 28 Nov 2024 to 1 Feb 2025.
- 24 Jan 2025 Planned primary completion date changed from 28 Nov 2024 to 1 Feb 2025.